4915-21-3Relevant articles and documents
Radical couplings as key steps for the preparation of derivatives of nonactic acid
Loiseau, Francois,Simone, Jean-Mary,Carcache, David,Bobal, Pavel,Neier, Reinhard
, p. 121 - 129 (2007)
Free radical couplings from furan, as cheap starting material, were studied in view of developing a rapid strategy en route to the synthesis of derivatives of nonactin. The chain containing the alcohol function was introduced in one or two steps in 86% yi
-
Ryan et al.
, p. 2037 (1940)
-
Synthesis method of furan acetate compound
-
Paragraph 0016, (2021/06/06)
The invention discloses a synthesis method of a furan acetate compound, wherein the synthesis method comprises the steps: by taking a furfuryl alcohol compound as a raw material, carbon monoxide gas as a carbonyl source and an ester compound as an additive, carrying out carbonylation reaction in an organic solvent under the action of a catalyst to obtain the furan acetate compound, wherein the catalyst is a combination of alkali, palladium metal salt and a phosphine-containing ligand. The furfuryl alcohol compound is used as the raw material, the furan acetate compound is synthesized by increasing the carbon number of the furfuryl alcohol compound through carbonylation, the synthesis process is simple, the synthesis condition is mild, the cost is low, the yield of furfuryl acetate is high, and meanwhile conversion and utilization of renewable resource biomass furfuryl alcohol are achieved.
Method for producing hematopoietic stem cells using pyrazole compounds
-
Page/Page column 185, (2016/01/10)
An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R8 are as defined in the description).